RxDoctor Payments Data

Grace Devine

Physician Assistant · Akron, OHNPI 1144974635

Payments from drug & device makers

$8,945in general payments, 2019–2025

Across 440 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$970
  • E.r. Squibb & Sons, L.L.C.$807
  • LEO Pharma Inc.$755
  • Amgen$653
  • Regeneron Healthcare Solutions, Inc.$586
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$8,32093%
  • Education$6247%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,945 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$23,711
Medicare patients
129
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa46$958,115
Dupixent PenDupilumab136$496,185
Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-5014$419,276
Taltz AutoinjectorIxekizumab25$225,526
TremfyaGuselkumab12$149,976
OtezlaApremilast31$147,606
Dupixent SyringeDupilumab14$49,846
OpzeluraRuxolitinib Phosphate21$42,052
VtamaTapinarof13$17,664
Tacrolimus37$7,211
Clobetasol Propionate182$6,263
Fluorouracil47$3,524
Ketoconazole193$3,283
Tretinoin27$2,615
Triamcinolone Acetonide126$2,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$970$149,97612 claims
AmgenOtezla$653$147,60631 claims
Incyte CorporationOpzelura$419$42,05221 claims
Dermavant Sciences, Inc.Vtama$90$17,66413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →